Thrombosis research
-
Thrombosis research · Jan 2007
Contribution of multiple thrombophilic and transient risk factors in the development of cerebral venous thrombosis.
Cerebral venous thrombosis (CVT), deep vein thrombosis (DVT) and/or pulmonary embolism (PE) have been associated with thrombophilic defects. However, in contrast to DVT or PE, CVT is a rare disease. We performed a study to identify differences in thrombotic risk profile, predisposing to CVT rather than DVT or PE, particularly the contribution of oral contraception and 11 thrombophilic defects. ⋯ We conclude that a majority of CVT and DVT or PE patients show single or multiple thrombophilic defects. At presentation, oral contraceptive intake was observed more frequently in CVT patients. However, no differences were observed in thrombotic risk profile between both groups of comparable age. Hence, additional unknown risk factors should be considered to explain the different sites of thrombosis in these patients.
-
Thrombosis research · Jan 2007
Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
Various dysfibrinogenemias have been described worldwide. This paper describes two new cases of dysfibrinogenemia identified in the Czech Republic. ⋯ The case of dysfibrinogenemia Aalpha R16C-fibrinogen Nový Jicín and the case of dysfibrinogenemia Aalpha R16H were found by routine coagulation testing and were genetically identified.
-
Thrombosis research · Jan 2007
A novel intermittent mechanical compression device for stasis prevention in the lower limbs during limited mobility situations.
Intermittent pneumatic mechanical compression is commonly applied to obviate venous stasis in patients with increased risk of thromboembolism. Aviafit is a small battery-operated intermittent compression device using a patented mechanical, non-pneumatic technology. Our objective was to examine its ability to prevent venous stasis. ⋯ The lightweight, battery-operated and user-friendly Aviafit can provide the same hemodynamic benefits as larger conventional intermittent pneumatic compression devices. Its potential advantages for prophylaxis of thromboembolism and increased compliance in rehabilitation and homecare, and for use during long periods of immobility such as during flights, are evident.
-
Thrombosis research · Jan 2007
Cinnamaldehyde reduction of platelet aggregation and thrombosis in rodents.
Cinnamaldehyde (CA) has been reported to inhibit in vitro aggregation in human and rabbit platelets; however, little is known about the antithrombotic activities of CA in vivo. ⋯ The results demonstrate that CA may be a promising antithrombotic agent, and its antithrombotic activity may be due to anti-platelet aggregation activity in vitro and in vivo.